Bellvitge Biomedical Research Institute (IDIBELL)

If you are the contact person for this centre and you wish to make any changes, please contact us.

SMC participants

Coordinator of the Neuro-oncology Unit of the Bellvitge Biomedical Research Institute (IDIBELL) and researcher of the Neuroplasticity and Regeneration Group of the Autonomous University of Barcelona

Head of the Cancer Virotherapy Group at the Bellvitge Biomedical Research Institute (IDIBELL).

Emeritus researcher at the Catalan Institute of Oncology (ICO), senior researcher at the Bellvitge Biomedical Research Institute (IDIBELL) and lecturer in the Faculty of Health Sciences at the Universitat Oberta de Catalunya (UOC)

Contents related to this centre
mouse

A drug in gel form cured 100 percent of mice with a very aggressive brain tumor. The authors hope that this is a first step towards helping human patients with glioblastoma, one of the most dangerous brain tumors in humans. The article is published today in PNAS.

Cáncer de mama

A phase 2 clinical trial has tested a type of immunotherapy based on oncolytic viruses in combination with chemotherapy for the treatment of triple-negative breast tumours. The results are published in the journal Nature Medicine.

vaccine

In the United States, the human papillomavirus vaccine began to be recommended in 2006 for girls aged 9-26 years. A study published in the journal JAMA Health Forum concludes that the campaign significantly reduced the risk of HPV infection in vaccinated women. In addition, herd immunity reduced the likelihood of infection in unvaccinated women.